Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001230466 | SCV001402947 | likely pathogenic | Leber congenital amaurosis 2; Retinitis pigmentosa 20 | 2024-01-30 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 1 of the RPE65 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in RPE65 are known to be pathogenic (PMID: 9326941, 9501220, 9843205, 18632300). This variant is present in population databases (rs778768116, gnomAD 0.009%). Disruption of this splice site has been observed in individual(s) with clinical features of RPE65-related conditions (PMID: 31429209). ClinVar contains an entry for this variant (Variation ID: 957480). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Baylor Genetics | RCV003469408 | SCV004209299 | pathogenic | Leber congenital amaurosis 2 | 2022-05-26 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001833994 | SCV002092785 | likely pathogenic | Leber congenital amaurosis | 2021-04-21 | no assertion criteria provided | clinical testing |